Search Results for "actemra"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for actemra. Results 11 to 14 of 14 total matches.
See also: tocilizumab
Sarilumab (Kevzara) for Polymyalgia Rheumatica
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
inhibitor tocilizumab (Actemra) and the CD20
inhibitor rituximab (Rituxan, and biosimilars) have also ...
The FDA has approved the interleukin (IL)-6 inhibitor
sarilumab (Kevzara – Sanofi/Regeneron) for treatment
of polymyalgia rheumatica (PMR) in adults who
had an inadequate response to corticosteroids or
cannot tolerate a corticosteroid taper. Sarilumab is
the first biologic drug to be approved for treatment
of PMR; it was previously approved for treatment of
rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8 doi:10.58347/tml.2024.1702c | Show Introduction Hide Introduction
Idecabtagene Vicleucel (Abecma) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
. CRS has been successfully
treated with the IL-6 receptor antagonist tocilizumab
(Actemra ...
The FDA has approved idecabtagene vicleucel
(Abecma – BMS), a B-cell maturation antigen (BCMA)-directed genetically-modified cellular product, for
treatment of relapsed or refractory multiple myeloma in
adults who received ≥4 prior lines of therapy, including
a proteasome inhibitor, an immunomodulatory drug,
and an anti-CD38 monoclonal antibody. Abecma is
an individualized cellular product prepared from the
patient’s own T cells, which are genetically modified
to express chimeric antigen receptors (CAR) and
then infused back into the patient. Ciltacabtagene
autoleucel...
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
weeks 3206.80
(Sanofi/Regeneron) pens and syringes
Tocilizumab8 – Actemra 80, 200, 400 mg single-dose ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
has been successfully treated with the
IL-6 receptor antagonist tocilizumab (Actemra), with
or without corticosteroids ...
The FDA has approved ciltacabtagene autoleucel
(Carvykti – Janssen), a B-cell maturation antigen
(BCMA)-directed genetically-modified cellular product,
for treatment of relapsed or refractory
multiple myeloma in adults who received ≥4 prior
lines of therapy, including a proteasome inhibitor,
an immunomodulatory drug, and an anti-CD38
monoclonal antibody. Carvykti is an individualized
cellular product prepared from the patient's own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. Idecabtagene...